Who owns Lexeo Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of LXEO from SEC Form 13F filings across 141 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 141 institutions disclosed 88.2M shares of Lexeo Therapeutics, Inc. worth $410.9M — about 103.1% of shares outstanding; the largest disclosed holder is MONTANOVA CAPITAL, LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
141
13F holders
$410.9M
value, 2026 filers
103.1%
of shares outstanding (88.2M sh)
27
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of LXEO's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | MONTANOVA CAPITAL, LLC | 6.4M | $29.7M | 0.5% | 7.5% | +410.7% |
| 2 | Affinity Asset Advisors, LLC | 5.8M | $27.0M | 1.2% | 6.8% | +15.0% |
| 3 | BlackRock, Inc. | 5.7M | $26.7M | 0.0% | 6.7% | +12.3% |
| 4 | RA CAPITAL MANAGEMENT, L.P. | 5.0M | $23.3M | 0.2% | 5.8% | 0.0% |
| 5 | Frazier Life Sciences Management, L.P. | 4.8M | $22.5M | 0.5% | 5.6% | +9.0% |
| 6 | STATE STREET CORP | 4.4M | $20.3M | 0.0% | 5.1% | +22.0% |
| 7 | Vestal Point Capital, LP | 4.3M | $20.1M | 0.5% | 5% | -3.5% |
| 8 | Paradigm Biocapital Advisors LP | 4.2M | $19.4M | 0.4% | 4.9% | -32.5% |
| 9 | Jupiter Topco LLCNEW | 4.0M | $18.4M | 0.0% | 4.6% | new |
| 10 | ORBIMED ADVISORS LLC | 3.9M | $18.4M | 0.3% | 4.6% | +9.6% |
| 11 | CITADEL ADVISORS LLC | 3.9M | $18.1M | 0.0% | 4.6% | +1.7% |
| 12 | VANGUARD CAPITAL MANAGEMENT LLC | 3.1M | $14.6M | 0.0% | 3.7% | +4.0% |
| 13 | MILLENNIUM MANAGEMENT LLC | 2.8M | $13.2M | 0.0% | 3.3% | +75.7% |
| 14 | Woodline Partners LP | 2.5M | $11.6M | 0.0% | 2.9% | -9.1% |
| 15 | Balyasny Asset Management L.P. | 2.4M | $11.2M | 0.0% | 2.8% | +51.8% |
| 16 | GOLDMAN SACHS GROUP INC | 2.1M | $10.0M | 0.0% | 2.5% | +10.2% |
| 17 | 683 Capital Management, LLC | 1.9M | $8.7M | 0.4% | 2.2% | +56.3% |
| 18 | GEODE CAPITAL MANAGEMENT, LLC | 1.7M | $8.1M | 0.0% | 2% | +15.5% |
| 19 | ADAR1 Capital Management, LLC | 1.6M | $7.3M | 0.3% | 1.8% | +6.7% |
| 20 | Avoro Capital Advisors LLC | 1.5M | $6.9M | 0.1% | 1.7% | -20.6% |
| 21 | Qube Research & Technologies Ltd | 1.4M | $6.4M | 0.0% | 1.6% | +195.6% |
| 22 | Nantahala Capital Management, LLC | 1.3M | $6.1M | 0.2% | 1.5% | +8.3% |
| 23 | DIMENSIONAL FUND ADVISORS LP | 1.3M | $6.0M | 0.0% | 1.5% | +16.6% |
| 24 | Spruce Street Capital LP | 928,593 | $4.3M | 0.8% | 1.1% | 0.0% |
| 25 | Blackstone Inc. | 904,959 | $4.2M | 0.0% | 1.1% | 0.0% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.